World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Original Article

Volume 4, Number 6, December 2013, pages 221-229


Comparison of Neoadjuvant Intraarterial Chemotherapy Versus Concurrent Chemoradiotherapy in Patients With Stage IIIB Uterine Cervical Cancer

Figures

Figure 1.
Figure 1. The trial profile of the flow of patients.
Figure 2.
Figure 2. Kaplan-Maier estimates of overall survival for patients who received IA-NAC or CCRT. The 5-year survival rate was 62.4% with IA-NAC and 51.1% with CCRT.
Figure 3.
Figure 3. Kaplan-Maier estimates of disease-free survival for patients who received IA-NAC or CCRT. The 5-year survival rate was 44.5% with IA-NAC and 46.9% with CCRT.
Figure 4.
Figure 4. Kaplan-Maier estimates of overall survival for patients who received IA-NAC + ARH or IA-NAC + RT. The 5-year survival rate was 75.0% with IA-NAC and 55.3% with CCRT.
Figure 5.
Figure 5. Kaplan-Maier estimates of disease-free survival for patients who received IA-NAC + ARH or IA-NAC + RT. The 5-year survival rate was 58.3% with IA-NAC and 37.6% with CCRT.

Tables

Table 1. Clinical Characteristics of All the Patients With Stage IIIB Cervical Cancer
 
IA-NAC group (n = 38)CCRT group (n = 38)P value
Age (years)
Mean ± SD56.2 ± 9.058.9 ± 12.40.612
ECOG performance status (n, %)
  037 (97.4%)60 (93.5%)0.857
  1-21 (2.6%)4 (6.5%)
Tumor dimension (mm)
Mean ± SD55.6 ± 16.747.5 ± 14.90.012
Pelvic lymph node status (n, %)
  Negative23 (60.5%)54 (84.4%)0.071
  Positive15 (39.5%)11 (17.2%)
Serum SCC (ng/ML)
Mean ± SD25.1 ± 33.024.1 ± 38.80.893

 

Table 2. Clinical Characteristics Patients With Treated With IA-NAC
 
ARH group (n = 12)RT group (n = 26)P value
Age (years)
Mean ± SD53.7 ± 8.657.3 ± 9.10.246
ECOG performance status (n, %)
  012 (100%)26 (93.5%)0.857
  1-20 (0%)1(6.5%)
Tumor dimension (mm)
Mean ± SD53.8 ± 163756.4 ± 17.20.659
Pelvic lymph node status (n, %)
  Negative7 (58.3%)16 (61.5%)0.583
  Positive5 (41.7%)10 (38.5%)
Serum SCC (ng/ML)
Mean ± SD10.9 ± 10.231.6 ± 37.70.073

 

Table 3. Response to IA-NAC or CCRT
 
IA-NAC group (n = 38)CCRT group (n = 64)
No. of patients%No. of patients%
Complete response1539.42640.6
Partial response1847.43757.8
Stable disease513.211.6
Response rate3386.86398.4

 

Table 4. The Patterns of Failure and Death
 
OutcomeIA-NAC group (n = 38)CCRT group (n = 64)
No. of patients%No. of patients%
Progression status
  Relapse2033
    Local923.72234.3
    Distant923.769.3
    Combined25.223.1
  No evidence of disease1847.43148.3
Survival status
  Dead1744.73453.1
  Alive2155.33046.9